Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase. clinical trial.

被引：0
|
作者：
Zhang, Yan-Feng
Li, Xiao-Bing
Hong, Yong-Gui
Li, Xiao-Ming
Liang, Wei-Min
Zheng, Zhi-Xin
Yang, Guang-Yi
Wen, Yan-Yan
Cao, Heng
Wu, Wei-Long
Su, Wen-Zhong
机构：
[1] Anyang Tumor Hosp, Anyang, Peoples R China
[2] Anyang Tumour Hosp, Anyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [21] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [22] Multi-omics analysis of tislelizumab plus nab-paclitaxel and cisplatin as neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A prospective single-arm phase II trial
    Xie, Z.
    Zhang, W.
    Chen, X.
    Wang, X.
    Liu, S.
    Yi, J.
    An, C.
    Lu, H.
    Yao, J.
    Zhu, H.
    Xie, T.
    Tang, L.
    He, X.
    Shi, Y.
    Gui, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S641 - S641
  • [23] A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin
    Qi, Yu
    Yang, Yang
    Li, Weihao
    Yue, Songwei
    Ma, Yihui
    Liu, Donglei
    He, Zhanfeng
    Chen, Lidong
    Li, Wencai
    Zhao, Song
    Wang, Congcong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
    Qiu, Tianzhu
    Mingjie, Lu
    Dong, Yuwen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
  • [25] Clinical outcomes following neoadjuvant nab-paclitaxel and cisplatin chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Yun, Fan
    Hua, Jiang You
    Min, Zhou Xin
    Xun, Chen Qi
    Yu, Huang Zhi
    Lei, Gong
    Yuan, Yang Hai
    Shi, Liu Jin
    Chen, Chen Peng
    Qiang, Zhao
    Mao, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin
    Qi, Yu
    Yang, Yang
    Li, Weihao
    Yue, Songwei
    Ma, Yihui
    Liu, Donglei
    He, Zhanfeng
    Chen, Lidong
    Li, Wencai
    Li, Linghua
    Zhao, Song
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase., single-arm, exploratory research.
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
    Guo, Wen-Zhi
    Li, Lu-Hao
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Pan, Jie
    Jin, Shui-Ling
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial
    Zhang, Zhiye
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Chen, Yanfeng
    Yang, Ankui
    Mao, Yan-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345